# Fortis Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fortis-therapeutics

- Industry: Biotechnology
- Headquarters: US
- Website: www.fortistx.com
- Total disclosed funding: $58M
- Latest round: Series A (Mar 29, 2021)
- Investors on record: 7

## About

Fortis Therapeutics, Inc. is a US-based biotechnology company focused on developing precision therapies targeting CD46 proteins to enhance cancer treatment outcomes, particularly in late-stage prostate cancer and multiple myeloma.Founded in 2016 and headquartered in the US, Fortis Therapeutics, Inc. is dedicated to advancing proprietary therapeutics targeting CD46 proteins. The company underwent a pivotal Series A funding round in March 2021, raising USD 40.000 mn from investors such as Multiple Myeloma Research Foundation and Avalon Ventures. The firm has completed a total of 2 deals to date.Fortis Therapeutics specializes in the development of proprietary precision therapies targeting CD46 proteins, focusing on transforming cancer treatment outcomes. Their core offerings include novel anti-CD46 therapeutics specifically designed to treat late-stage prostate cancer and multiple myeloma. These therapies utilize advanced technology to precisely direct treatment to cancerous cells while minimizing damage to healthy tissues, thereby improving patient quality of life and treatment efficacy. The company aims to serve a diverse client base, including healthcare providers, hospitals, and research institutions, primarily within the United States and regions with advanced healthcare infrastructure such as Europe and Asia. The release of these targeted therapies is positioned to address critical unmet needs in oncology, enhancing treatment strategies for patients who have limited options.Fortis Therapeutics recently closed a USD 40.000 mn Series A financing round to advance its pipeline of anti-CD46 therapeutics. Revenue generation is anticipated through strategic partnerships, licensing agreements, and collaborations with pharmaceutical companies and healthcare institutions interested in their innovative products. The company’s business model is structured around B2B transactions, where healthcare providers and research institutions acquire the therapeutics for clinical use and trials. These transactions may include frameworks for milestone payments and royalties based on the commercial success of their therapies. Given the proprietary nature of their products, Fortis Therapeutics is positioned to establish advantageous pricing structures that reflect the unique value and efficacy of their targeted treatments within the oncology market.In March 2021, Fortis Therapeutics, Inc. raised USD 40.000 mn in Series A funding, which will be utilized to advance FOR46 in clinical trials targeting metastatic castration-resistant prostate cancer and relapsed or refractory multiple myeloma. The company plans to expand its product offerings by developing additional therapies targeting various cancers and aims to penetrate new markets in Europe and Asia by 2023.

## Funding rounds

- Series A, Mar 29, 2021, $40M — Avalon Ventures, Vivo Capital, OUP (Osage University Partners), Lilly Asia Ventures, Multiple Myeloma Research Foundation, Bregua Corporation, Fulcrum 2020, LLC
- Series A, Jun 6, 2016, $18M — Avalon Ventures, Vivo Capital, OUP (Osage University Partners), Lilly Asia Ventures, Bregua Corporation

## Investors

- Avalon Ventures (https://capitalatlas.ai/funds/avalon-ventures) — Series A
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series A
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A
- Bregua Corporation — Series A
- Multiple Myeloma Research Foundation — Series A
- Fulcrum 2020, LLC — Series A